Skip to main content
Equibles
PTN logo

PTN · Palatin Technologies Inc · Metrics

Track PTN — free

Use PTN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PTN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$5.49 -0.03 (-0.54%)
Rebalance outlook locked
Going-concern doubt — flagged Sep 28, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Based on the Company's available cash and cash equivalents as of June 30, 2026, management has concluded that substantial doubt exists about the Company's ability to continue as a going concern for one year from the date these consolidated financial statements are issued.”
View the 10-K filed Sep 28, 2026
Market Cap
$9.83M
Shares
1.78M
Volume · Oct 21 16.22K Avg daily vol (3M) 64.72K

PTN metrics

79 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$5.52
Market cap
$9.83M

Price action

20 metrics
Price change (1W)
-32.6%
Price change (30D)
-46.0%
Price change (3M)
-36.0%
Price change (6M)
-74.7%
Price change (YTD)
-64.1%
Price change (1Y)
-18.0%
Trailing year
Price change (5Y)
—
52-week high
$28.00
52-week low
$5.52
Change from 52-week high
-80.3%
Change from 52-week low
+0.0%
Annualized volatility
131.7%
Annualized volatility (3M)
107.6%
Beta
0.1
RSI (14D)
22.3
Price vs SMA 50
-44.1%
Price vs SMA 200
-62.0%
Avg volume (3M)
64,716
Relative volume
1.0
Average dollar volume
$725,136

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
1.78M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
0.4×
reciprocal yield 278.0%
EV / EBITDA
—
EV / EBIT
—
P / sales
1.2×
reciprocal yield 82.8%
P / book
1.6
reciprocal yield 62.7%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-78.5%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
3.6×
reciprocal yield 28.1%
EV / revenue historical average (5Y)
21.4×
reciprocal yield 4.7%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-09-28

Profitability

9 metrics
Gross margin
—
Operating margin
-98.2%
Trailing 12 months
Net margin
-94.9%
Gross profit (TTM)
$4.39M
Operating profit (TTM)
−$8.67M
Net income (TTM)
−$8.38M
Trailing 12 months
Diluted EPS (TTM)
$-2.96
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$8.02
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-0.21
EBITDA per diluted share (TTM)
$-0.18
Net income per diluted share (TTM)
$-0.12
Operating cash flow per diluted share (TTM)
$-5.21
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$5.43
Stock compensation per diluted share (TTM)
$0.50
Book value per share
$3.76

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
$8.83M
Trailing 12 months
EPS growth YoY
-252.9%
Shares change YoY
+642.5%
Year over year · more shares
Revenue CAGR (3Y)
+22.1%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-125.3%
Return on assets
-98.3%
Debt / equity
0.0
Current ratio
4.6
EBITDA (TTM)
−$8.61M
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
-1,288.8
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$7.49M
Latest balance sheet
Cash & equivalents
$7.49M
Total assets
$8.52M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$13.53M
Capital expenditures (TTM)
—
R&D (TTM)
$12.37M
SG&A (TTM)
$7.45M
Stock compensation (TTM)
$1.33M
R&D / revenue
140.1%
Stock compensation / revenue
15.1%

Ownership (13F)

9 metrics
13F filers
26
13F filer change QoQ
0
Institutional ownership
38.5%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
24.3%
Private-fund adviser ownership
24.3%
Active holders' share change QoQ
-13.3%
Holder tenure
2.3
Price vs estimated holder cost
-23.1%

Ownership (registered funds)

1 metrics
Index-fund ownership
2.2%

Short interest

3 metrics
Short interest
20.5%
Latest settlement · 8.0 days to cover
Days to cover
8.0d
Short-squeeze score
66 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 911216 CUSIP 696077601 13F (30d) 2 filings 2 filers Visit website Investor relations